Ascendent Capital Partners has successfully acquired Hollysys Automation Technologies Ltd. for approximately US$1.66 billion, enhancing its capabilities within China's growing automation and biopharmaceutical sectors.

Target Information

Hollysys Automation Technologies Ltd. is a prominent provider of automation control systems in China, recognized for its innovative solutions across various sectors. Established in 1993, Hollysys boasts a strong portfolio that addresses complex automation needs, particularly in industries such as manufacturing, transportation, and energy.

The company has earned a reputation for utilizing cutting-edge technology to enhance operational efficiency and reliability. Hollysys has been a key player in China's automation landscape, contributing to myriad projects that have fostered advancements in industrial automation processes.

Industry Overview in China

The automation industry in China has witnessed significant growth due to the country's ongoing industrial transformation and modernization efforts. Robust investment in technology infrastructure, fueled

View Source

Similar Deals

AstraZeneca FiberGen

2025

Buyout Proprietary & Advanced Pharmaceuticals China
Novartis SanReno Therapeutics

2024

Buyout Proprietary & Advanced Pharmaceuticals China
GL Capital SciClone Pharmaceuticals

2023

Buyout Proprietary & Advanced Pharmaceuticals China
GL Capital Group Huizhou Foryou Medical Devices Co., Ltd

2023

Buyout Medical Devices & Implants China
Hygeia Healthcare Suzhou Yongding Hospital

2021

Buyout Hospitals, Clinics & Primary Care Services China

Ascendent Capital Partners

invested in

Hollysys Automation Technologies Ltd.

in 2024

in a Buyout deal

Disclosed details

Transaction Size: $1,660M

Enterprise Value: $1,660M

Equity Value: $1,660M

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert